Recent Updates
Recently added Catalysts
MRVI Positive Sentiment

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

Tuesday, September 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: TriLink BioTechnologies has received a new patent from the China National Intellectual Property Administration for its CleanCap® technology. This patent, which is the second granted in China within a short time frame, strengthens TriLink's intellectual property rights and expands its global market presence. The patent focuses on methods for synthesizing 5'-capped RNAs.

Market Sentiment Analysis

POSITIVE FACTORS

  • TriLink secures a new patent in China, enhancing its IP portfolio.
  • The patent reinforces CleanCap® technology's global protection.
  • This is the second CleanCap® patent granted in China recently.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5., named "Compositions and Methods for Synthesizing 5'-Capped RNAs." The patent marks TriLink's second granted CleanCap® patent in China within a matter of months, and expands

Frequently Asked Questions

What is the new patent granted to TriLink about?

The new patent focuses on compositions and methods for synthesizing 5'-capped RNAs.

How many CleanCap® patents has TriLink received in China?

TriLink has received two CleanCap® patents in China within a short period.

What does the new patent enhance for TriLink?

The patent enhances TriLink's intellectual property protection for its CleanCap® technology.

Which organization granted the patent to TriLink?

The patent was granted by the China National Intellectual Property Administration (CNIPA).

ShareAdd on Google
Tags: MRVI TriLink BioTechnologies CleanCap® China patent intellectual property
Last updated: Sep 29, 2026

Biotech snapshot

Cash runway
$70M liquidity · $0M/mo burn
Low dilution risk